NCT03785184 is a Phase 2 clinical trial of venetoclax in Multiple Myeloma, sponsored by AbbVie.

Who is sponsoring NCT03785184?

NCT03785184 is sponsored by AbbVie.

What drugs are being tested in NCT03785184?

Interventions in NCT03785184: venetoclax, lenalidomide, dexamethasone.

What condition does NCT03785184 study?

NCT03785184 studies Multiple Myeloma.

Is NCT03785184 still recruiting?

NCT03785184 is currently withdrawn. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT03785184

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Withdrawn Phase 2 Last updated 28 August 2019

What this trial tests

Phase 2 trial testing venetoclax in Multiple Myeloma. Withdrawn.

Timeline

29 April 2019

Primary endpoint
22 August 2019

22 August 2019

Quick facts

Lead sponsor	AbbVie
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	29 April 2019
Primary completion	22 August 2019
Estimated completion	22 August 2019
Sites	22 locations across Canada, United States, Australia, Spain

Drugs / interventions tested

venetoclax (venetoclax) — full drug profile →
lenalidomide — full drug profile →
dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

AbbVie — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM). This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.
Sgherza N, Curci P, Rizzi R, Musto P. · · 2021 · cited 2× · PMID 34660279 · DOI 10.3389/fonc.2021.716751

Verify or expand the search:

Other trials of venetoclax

Trials testing the same drug.

NCT06508489 — A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological · Phase 1, PHASE2 · terminated
NCT06361329 — Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL · Phase 3 · recruiting
NCT06544109 — Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients · Phase 2, PHASE3 · enrolling by invitation
NCT05201066 — Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by · Phase 2 · active not recruiting
NCT05503355 — A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML · Phase 1, PHASE2 · unknown

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03785184 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing